Click HERE to register.

Join William D. Tap, MD for this PeerView live web broadcast that will feature a panel of leading clinicians providing insights on important medical evidence supporting targeted agents in TGCT, and modern, practical recommendations for overcoming patient care challenges in the management of TGCT. The panel will also provide a multidisciplinary perspective on real-world clinical scenarios and discuss how novel targeted therapeutics have enhanced a long-standing treatment landscape. Don’t miss this opportunity to see how the experts approach this challenging disorder!

Join Us for One of Two Web Broadcasts

• Thursday, November 19, 2020: 3:00–4:30 PM EST (This event is being held in conjunction with the CTOS Virtual Annual Meeting)
• Wednesday, December 2, 2020: 7:00–8:30 PM EST

Activity Description

Tenosynovial giant cell tumor (TGCT) is a rare and typically benign disorder that affects synovium-lined joints, bursae, and tendon sheaths. TGCT can result in significant morbidity and reduced quality of life for patients, particularly in cases of recurrent disease. Recent advances in the understanding of tumor biology, specifically the overexpression of colony-stimulating factor 1 (CSF1), have led to the validation of novel targeted therapies that are effective in patients with TGCT, especially those who are unlikely to benefit from surgical interventions. As a consequence, modern management protocols—undergirded by accurate diagnostic/prognostic modelling—have expanded to include targeted agents as part of a truly multimodal care model in the care of TGCT.

Target Audience

This activity has been designed to meet the educational needs of oncologists, orthopedic oncologists, orthopedic surgeons, pathologists, and other clinicians involved in the management of musculoskeletal tumors.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe the clinical signs and symptoms of localized and diffuse tenosynovial giant cell tumor (TGCT), including recurrent disease
• Explain the biologic rationale and clinical evidence for the use of targeted options in the management of TGCT
• Integrate targeted options into the management of TGCT patients who are unlikely to benefit from surgical interventions
• Recommend multidisciplinary approaches for the management of TGCT, including localized and diffuse disease

Faculty

Chair & Presenter

William D. Tap, MD
Memorial Sloan Kettering Cancer Center
New York, New York

Presenters

Nicholas M. Bernthal, MD
UCLA Department of Orthopaedic Surgery
David Geffen School of Medicine at UCLA
Los Angeles, California

Andrew J. Wagner, MD, PhD
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Accreditation

The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™.